Neuroectodermal Tumors, Primitive

• 

  Subject Areas on Research

  • A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. 
  • CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. 
  • Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. 
  • Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors. 
  • Ellen, a 12-year-old girl, was given a diagnosis of a primitive neuroectodermal tumor. 
  • Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. 
  • Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction. 
  • Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. 
  • Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. 
  • Glioneuronal tumors of the central nervous system. 
  • High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. 
  • Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. 
  • Intracranial Ewing sarcoma. 
  • Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC. 
  • Intraocular Teratoid Medulloepithelioma Presenting With a Completely Rhabdomyosarcomatous Distant Metastasis. 
  • Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. 
  • Molecular phenotype of simian virus 40 large T antigen-induced primitive neuroectodermal tumors in four different lines of transgenic mice. 
  • Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents. 
  • Patterns of care in adult medulloblastoma: results of an international online survey. 
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 
  • Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). 
  • Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. 
  • Primary intracranial Ewing's sarcoma with unusual features. 
  • Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. 
  • Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. 
  • The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial. 
  • The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. 
  • White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor.